MACROLIDES IN ASTHMA (MIA)

大环内酯类药物治疗哮喘 (MIA)

• 批准号: 7607712
• 负责人: Stephen P Peters
• 金额: $ 0.31万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607712
• 关键词: Asthma; Biopsy Specimen; Bronchoalveolar Lavage Fluid; Chlamydia; Chlamydophila pneumoniae; Chronic; Chronic lung disease; Clarithromycin; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Environmental Risk Factor; Etiology; Funding; Grant; Infection; Institution; Macrolides; Mycoplasma; Mycoplasma pneumoniae; Numbers; Organism; Patients; Placebos; Play; Polymerase Chain Reaction; Reporting; Research; Research Personnel; Resources; Respiratory Tract Infections; Role; Seroprevalences; Severities; Source; Syndrome; United States National Institutes of Health; Viral; Week; asthmatic patient; cofactor; fluticasone; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Asthma is a prevalent chronic lung disease. While the etiology of this syndrome is at present incompletely defined, a number of host and environmental factors likely interact to cause the asthma clinical syndrome. Respiratory tract infections, both viral and bacterial, have been postulated to play a role in modulating asthma onset and severity. Chronic airway infections with either Mycoplasma pneumoniae or Chlamydia pneumoniae have been implicated as an important cofactor in asthma. Martin and colleagues reported on the relationship between airway infection with mycoplasma or chlamydia and asthma in 55 chronic stable asthmatic subjects. Thirty-one of these 55 asthmatic patients (56.4%) had positive polymerase chain reaction (PCR) results for mycoplasma (n=25) or chlamydia species (n=7), primarily in endobronchial biopsy specimens or bronchoalveolar lavage fluid. By comparison, only 1 of 11 healthy control subjects had positive PCR results for mycoplasma species. Seroprevalence of these organisms did not differ significantly between asthmatics and controls. To evaluate, in an exploratory clinical trial, whether chronic airway infection with Mycoplasma pneumoniae or Chlamydia pneumoniae is a determinant of clinical response to clarithromycin in patients with asthma. Specific Aim 1a: to evaluate the effect on asthma control of 16 weeks of randomly allocated clarithromycin or placebo added to fluticasone in subjects with suboptimally controlled asthma and M. pneumoniae or C. pneumoniae airway infection. Specific Aim 1b: to evaluate the effect on asthma control of 16 weeks of randomly allocated clarithromycin or placebo added to fluticasone in uninfected, suboptimally controlled asthmatics.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 哮喘是一种流行的慢性肺部疾病。虽然该综合征的病因目前尚未完全确定，但许多宿主和环境因素可能相互作用，导致哮喘临床综合征。病毒性和细菌性呼吸道感染被认为在调节哮喘发作和严重程度方面发挥着作用。 肺炎支原体或肺炎衣原体的慢性气道感染被认为是哮喘的重要辅助因子。 Martin 及其同事报告了 55 名慢性稳定哮喘受试者的气道支原体或衣原体感染与哮喘之间的关系。其中三十一个 55 名哮喘患者 (56.4%) 的支原体 (n=25) 或衣原体 (n=7) 聚合酶链反应 (PCR) 结果呈阳性，主要存在于支气管内活检标本或支气管肺泡灌洗液中。相比之下，11 名健康对照受试者中只有 1 名支原体 PCR 结果呈阳性。血清流行率 这些微生物的数量在哮喘患者和对照组之间没有显着差异。 在一项探索性临床试验中评估肺炎支原体或肺炎衣原体的慢性气道感染是否是哮喘患者对克拉霉素临床反应的决定因素。 具体目标 1a：评估随机分配的克拉霉素或安慰剂加氟替卡松 16 周对哮喘控制不佳且患有肺炎支原体或肺炎衣原体气道感染的受试者的哮喘控制效果。 具体目标 1b：评估随机分配的克拉霉素或安慰剂加氟替卡松 16 周对未感染、控制不佳的哮喘患者的哮喘控制效果。